Biolab announces executives João Bezerra Leite and Ricardo Durazzo as members of the Advisory Board
After the new CEOBiolab is moving forward with its strategic restructuring process with the aim of strengthening its sustainable growth. The Advisory Board continues to be chaired by Ana Karina Bortoni, formerly of McKinsey and BMG, and is made up of the partners, with the addition of two independent directors: João Bezerra Leite and Ricardo Durazzo.
João has a solid 36-year career as CTO (Chief Technology Officer) at Itaú Unibanco and a deep knowledge of the Technology, Banking, Fintech and Telecommunications sectors. He also currently sits on the boards of Banco Carrefour, Nuvini, Surf Telecom and TQI, where he stands out for his pragmatic profile and strategic use of technology to boost business.
"I'm very happy to take part in projects with purpose and impact, in an environment with solid values and surrounded by people who want to transform and from whom I can learn. I'm very happy and excited about the chance to be part of this super team," says João Bezerra.
With a track record of leadership in strategic consultancies such as McKinsey, Booz Allen & A.T. Kearney, Ricardo brings robust expertise in Industrial Operations, Supply Chain, Strategy, Innovation and Internationalization. He is recognized for his ability to pivot organizations, adding value at times of transformation.
"I was honored to be invited to join the Biolab team and I am delighted to accept this challenge. This is a company with a reputation and distinctive values - values that I share. I hope to be able to contribute to its development, seeking more sophisticated governance, a more far-reaching strategy and a more efficient operation," adds Ricardo.
About Biolab
Promoting a future with a better quality of life requires a tireless search for safe and innovative treatments. With this mission in mind, Biolab, a Brazilian pharmaceutical company founded in 1997 and with an international presence, invests in research and partnerships to overcome the growing challenges of human and animal health.
With around 4,000 employees and the 4th largest sales force in Brazil, Biolab is among the largest pharmaceutical companies in the country, operating in various specialties, such as dermatology, gynecology, orthopedics, gastroenterology, pediatrics, clinical medicine and the central nervous system, as well as being a leader in cardiology. The Biolab Genéricos, Avert Humana and Avert Biolab Saúde Animal business units contribute to a portfolio of more than 500 products.
Biolab is constantly growing. There are three production units, as well as a modern manufacturing complex under construction in Pouso Alegre (MG), the result of investments of R$ 1 billion, which will increase the company's manufacturing capacity fivefold. And it doesn't stop there: in Canada it is the first Brazilian pharmaceutical company with a Research Center and it acquired the company Exzell Pharma to expand its borders.
Long live evolution!
Find out more at www.biolabfarma.com.br and on social media: Instagram, Facebook and Linkedin.